wheel
1.6 years
67% of patients with bilateral GA lose the ability to drive*7
bcva_icon
2 years
50% of patients with GA lose 2 lines of vision†8
Geographic Atrophy (GA) Central fovea
2.5 years
for GA to reach
the central fovea‡9

GA progression can be unpredictable and may move faster than you think10

What may be
happening to
the retina
1_First Photo_FAF_Baseline_CMYK
2_Second Photo_FAF_7months_CMYK
3_Third Photot_FAF_1year 7months_CMYK
4_Sixth Photo_FAF_4years 3month_CMYK
What may be happening to your patient’s vision
1_GettyImages-1273666103_POV driving_v5 1_CMYK
2_GettyImages-1273666103_POV driving_v5 2_CMYK
3_GettyImages-1273666103_POV driving_v5 3_CMYK
4_GettyImages-1273666103_POV driving_v5 6_CMYK

Representation of vision loss for illustrative purposes only.

Representation of vision loss for illustrative purposes only.

patients_undiagnosed
~ 1.5 million patients in the US are thought to live with GA; up to 75% of patients may be undiagnosed.11,12

Early detection means early protection

A comprehensive eye examination with imaging can help with early detection, diagnosis, and monitoring of GA. GA is a heterogeneous disease, so it is important to be vigilant and look for key biomarkers in the imaging modalities you have in your office.6
Colour Fundus Photography
Color Fundus Photography (CFP)13
  1. Sharply demarcated, typically circular zone with increased choroidal vessel visibility
Fundus Autofluorescence
Fundus Autofluorescence (FAF)6
  1. Hypofluorescence with a sharply demarcated border
  2. Hyperfluorescence surrounding atrophic lesion can indicate lipofuscin accumulation and be prognostic of GA progression
Optical Coherence Tomography
Optical Coherence Tomography (OCT)14
  1. Choroidal hypertransmission defects
  2. RPE, photoreceptor, and choriocapillaris layer loss
*Retrospective cohort analysis of an EMR database in the United Kingdom, including 1901 patients with bilateral GA.
†Analysis of the Chroma, Spectri, and Proxima A trials, including 2062 patients with GA. 1.6 years represents the median (0.7-2.7 years).
‡Progression from noncentral to central GA was estimated from 397 AREDS participants in which GA was initially diagnosed during follow-up with no history of neovascularization.
RPE=retinal pigment epithelium.

Sign up for updates

Sign Up

Explore our efficacy data

Next Page
IMPORTANT SAFETY INFORMATION AND INDICATION
IMPORTANT SAFETY INFORMATION AND INDICATION
Contraindications
  • IZERVAY is contraindicated in patients with ocular or periocular infections and in patients with active intraocular inflammation.
Warnings and Precautions
  • Endophthalmitis and Retinal Detachments
    • Intravitreal injections, including those with IZERVAY, may be associated with endophthalmitis and retinal detachments. Proper aseptic injection technique must always be used when administering IZERVAY in order to minimize the risk of endophthalmitis. Patients should be instructed to report any symptoms suggestive of endophthalmitis or retinal detachment without delay and should be managed appropriately.
  • Neovascular AMD
    • In clinical trials, use of IZERVAY was associated with increased rates of neovascular (wet) AMD or choroidal neovascularization (7% when administered monthly and 4% in the sham group) by Month 12. Patients receiving IZERVAY should be monitored for signs of neovascular AMD.
  • Increase in Intraocular Pressure
    • Transient increases in intraocular pressure (IOP) may occur after any intravitreal injection, including with IZERVAY. Perfusion of the optic nerve head should be monitored following the injection and managed appropriately.
Adverse Reactions
  • Most common adverse reactions (incidence ≥5%) reported in patients receiving IZERVAY were conjunctival hemorrhage, increased IOP, blurred vision, and neovascular age-related macular degeneration.
INDICATION

IZERVAY™ (avacincaptad pegol intravitreal solution) is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD)

Please see full Prescribing Information for more information.

To request medical information, please call 1-800-727-7003 or send an email to medinfo.americas@astellas.com. To report an adverse event or product complaint, please call 1-800-727-7003 or send an email to safety-us@astellas.com.